August 18, 2016
11 am to 12 pm EDT

Sponsored by

Webinar Description:

Overcoming the Pain Points of Next Generation Sequencing-Based Clinical Diagnostic Testing. Next Generation Sequencing (NGS)-based diagnostics are increasingly being adopted by clinical pathology laboratories as critical tools in testing and treating cancer and inherited diseases. Unfortunately, the platforms, reagents and software are still not fully integrated for quality management. Additionally, due to their highly-multiplexed outputs, validation, performance tracking and troubleshooting remain a major pain point for laboratories. We will be discussing some typical clinical lab case studies and how SeraCare is actively working to provide solutions to some of the biggest lab challenges when it comes to NGS-based assays.

Learning Objectives:

• Using highly multiplexed reference materials to gain valuable insight to assay performance
• Shorter and more meaningful assay validations for your tumor profiling assays
• Tracking detailed NGS QC metrics improves lab efficiency

Speaker:

Russell Garlick, PHD

Chief Scientific Officer

SeraCare Life Sciences

Russell Garlick joined SeraCare as CSO in 2012 to focus on expanding the company’s technologies, R&D organization, and product development pipeline. Throughout his career he has worked on the development, regulatory approval, and launch of a variety of technologies and assays, including an HIV/AIDS patient management program, molecular genomics technologies, and HIV drug discovery systems. Prior to joining SeraCare, Dr. Garlick was co-founder of Life Sciences Group and served as CEO and CTO of Protein Forest, Inc. He has also held executive R&D positions at PerkinElmer Life Sciences and DuPont NEN Life Sciences. Dr. Garlick earned both his PhD and MS in biomedical sciences, medicinal chemistry from the Barnett Institute at Northeastern University, and his BS in biology from the University of Massachusetts Lowell.